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Interplay of myosin phosphatase 
and protein phosphatase-2A in the 
regulation of endothelial nitric-
oxide synthase phosphorylation 
and nitric oxide production
Róbert Bátori1, Bálint Bécsi1,2, Dénes Nagy1, Zoltán Kónya1, Csaba Hegedűs1, 
Zsuzsanna Bordán3, Alexander Verin3, Beáta Lontay1 & Ferenc Erdődi1,2
The inhibitory phosphorylation of endothelial nitric oxide (NO) synthase (eNOS) at Thr497 (eNOSpThr497) 
by protein kinase C or RhoA-activated kinase is a major regulatory determinant of eNOS activity. The 
signalling mechanisms involved in the dephosphorylation of eNOSpThr497 have not yet been clarified. 
This study identifies myosin phosphatase (MP) holoenzyme consisting of protein phosphatase-1 
catalytic subunit (PP1c) and MP target subunit-1 (MYPT1) as an eNOSpThr497 phosphatase. In support of 
this finding are: (i) eNOS and MYPT1 interacts in various endothelial cells (ECs) and in in vitro binding 
assays (ii) MYPT1 targets and stimulates PP1c toward eNOSpThr497 substrate (iii) phosphorylation 
of MYPT1 at Thr696 (MYPT1pThr696) controls the activity of MP on eNOSpThr497. Phosphatase 
inhibition suppresses both NO production and transendothelial resistance (TER) of ECs. In contrast, 
epigallocatechin-3-gallate (EGCG) signals ECs via the 67 kDa laminin-receptor (67LR) resulting in protein 
kinase A dependent activation of protein phosphatase-2A (PP2A). PP2A dephosphorylates MYPT1pThr696 
and thereby stimulates MP activity inducing dephosphorylation of eNOSpThr497 and the 20 kDa myosin II 
light chains. Thus an interplay of MP and PP2A is involved in the physiological regulation of EC functions 
implying that an EGCG dependent activation of these phosphatases leads to enhanced NO production 
and EC barrier improvement.
Endothelium-derived nitric oxide (NO) is an important gaseous mediator of numerous cardiovascular functions. 
The synthesis of NO from L-arginine is catalyzed by endothelial NO synthase (eNOS), therefore the regulation of 
eNOS activity is a key factor in the physiological control of NO level in the cells1. The activity of eNOS is depend-
ent on its subcellular localization2,3 and is also mediated by protein-protein interactions as well as by posttrans-
lational modifications4,5.
Among the posttranslational processes phosphorylation of eNOS at serine (Ser) and threonine (Thr) res-
idues bears special importance in the regulation of enzyme activity6. The major phosphorylation sites identi-
fied in eNOS are Ser116, Thr497, Ser617, Ser635 and Ser1179 (numbering the residues are based on the bovine 
isoform) and the numerous kinases implicated in the phosphorylation processes include AMP activated pro-
tein kinase (AMPK)7, protein kinase A (PKA)8, protein kinase B (PKB/Akt)9, protein kinase C (PKC)10, 
Ca2+-calmodulin-dependent kinase II11 and RhoA-activated kinase (ROCK)12. The influence of phosphorylation 
of the above sites on the activity of eNOS is under continuous evaluation and includes certain controversies4–6. 
Even though, it is generally accepted that increase in the level of phosphorylated Ser617 (eNOSpSer617), Ser635 
(eNOSpSer635) and Ser1179 (eNOSpSer1179) results in activation of eNOS, whereas enhanced phosphorylation of 
Ser116 (eNOSpSer116) or Thr497 (eNOSpThr497) has inhibitory impacts6. The kinases that phosphorylate eNOS at 
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the distinct sites are quite well characterized, but less is known about the protein phosphatases which catalyze the 
dephosphorylation processes. Protein phosphatase-1 (PP1), − 2A (PP2A) and − 2B (PP2B, also termed calcineu-
rin) are implicated in the dephosphorylation of eNOS and certain site-specificity of these phosphatases has also 
been claimed in previous reports. Thus, it is suggested that PP2B13 and/or PP2A14 dephosphorylate eNOSpSer116, 
PP110 and/or PP2B15 act on eNOSpThr497 and PP2A10,16 may be involved in eNOSpSer1179 dephosphorylation. Both 
PP1 and PP2A exist in the cells in various holoenzyme forms, however, still limited amount of data available on 
which PP1 or PP2A species are involved in the dephosphorylation of eNOS at the above phosphosites.
Phosphorylation/dephosphorylation of Thr497 appears to be a major factor in the regulation of eNOS activity. 
It is established that increase in the intracellular Ca2+ concentration contributes to eNOS activation17 as eNOS, to 
be fully active, requires binding of Ca2+-calmodulin (CaM) to a linker sequence separating the N- and C-terminal 
domains18. Increase in the level of eNOSpThr497 in endothelial cells in a PKC- or ROCK-dependent manner19, 
opposes CaM-binding leading to reduction in eNOS activity11. It is believed that one of the important deter-
minants in eNOS activity is the reciprocal phosphorylation of Thr497 and Ser1179, respectively, implying that 
during agonist stimulation of endothelial cells (ECs) dephosphorylation of eNOSpThr497 precedes phosphorylation 
at Ser117910,11,15. Accordingly, in bradykinin stimulated ECs activation of eNOS primarily involves dephospho-
rylation of eNOSpThr497 and the contribution of increased eNOSpSer1179 is assumed to be less significant11. It has 
also been proposed that eNOSThr497 phosphorylation may not exclusively act via suppressing CaM-binding only, 
but it might serve also as an intrinsic switch in determining whether eNOS generates NO or superoxide in cells20.
Despite the crucial importance of the phosphorylation/dephosphorylation of Thr497 in eNOS activity and 
functions, the phosphatase holoenzyme(s) as well as the signalling mechanism implicated in eNOSpThr497 dephos-
phorylation have remained to be elucidated. Several reports10,11,21 have established that PP1 type enzyme dephos-
phorylates eNOSpThr497, however, the mediatory role (direct or indirect) of PP2A or the CaM-dependent PP2B/
calcineurin could not be excluded either15.
The aim of the present study was to investigate if myosin phosphatase (MP) holoenzyme consisting of PP1 
catalytic subunit (PP1c), myosin phosphatase target subunit-1 (MYPT1) and a 20 kDa protein in smooth mus-
cles22,23, is involved in the dephosphorylation of eNOSpThr497. It is proven that the MP holoenzyme is an eNO-
SpThr497 phosphatase and MYPT1 targets PP1c to eNOSpThr497 substrate during dephosphorylation. Moreover, 
phosphorylation/dephosphorylation of MYPT1 at the inhibitory Thr696 residue parallels with changes in the 
eNOSpThr497 level confirming the involvement of MP in eNOSThr497 dephosphorylation. We provide evidence for 
the interplay of MP and PP2A in the dephosphorylation of eNOS in ECs. Epigallocatechin-3-gallate (EGCG), a 
green tea polyphenol, signals ECs via the 67-kDa laminin receptor (67LR) to activate a specific isoform of tri-
mer PP2A in a PKA dependent manner. The activated PP2A causes stimulation of MP through PP2A-induced 
dephosphorylation of MYPT1pThr696 which results in subsequent dephosphorylation of eNOSpThr497 and the 
20 kDa light chain of myosin II (MLC20) coupled to increased eNOS activity and NO production as well as 
improvement of the barrier function of ECs.
Results
Interaction of eNOS with myosin phosphatase target subunit-1 (MYPT1). It is generally accepted 
that most of the regulatory subunits in PP1 holoenzymes have a targeting role implying that they also interact 
with substrates and help PP1c to fulfil its catalytic action during the dephosphorylation process. In case of MP 
uncovering of MYPT1 binding protein partners led to the identification of several putative substrates24 and other 
interacting proteins important in the regulation of MP activity25. Thus, to prove eNOS as a possible substrate of 
MP we assessed initially if eNOS and MYPT1 interact in ECs or in tsA201 cells where these two proteins were 
co-expressed.
First, pull-down of eNOS from human umbilical vein EC (HUVEC) lysate by GST-MYPT1 was attempted 
capturing recombinant GST-MYPT1 and the associated endothelial proteins on glutathione-Sepharose (Fig. 1a). 
On Western blots eNOS was identified in the eluate using anti-eNOS suggesting its co-precipitation with 
GST-MYPT1, whereas no eNOS was detected in the control GST-pull-down fraction. Pull-downs from the lysates 
of tsA201 cells co-expressing both FLAG-MYPT1 and c-myc-eNOS proteins were analysed with anti-MYPT11–296 
and anti-eNOS (Fig. 1b and c), or with anti-FLAG or anti-c-myc antibodies (Fig. S1b) and these data confirmed 
reciprocal co-precipitation of c-myc-eNOS and FLAG-MYPT1 with each other. The whole blot images of GST- 
or GST-MYPT1 pull-downs, the expression pattern of FLAG-MYPT1 and myc-eNOS in tsA201 cells as well as 
control pull-downs from nontransfected tsA201 lysates with anti-FLAG and anti-c-myc antibodies are shown in 
Fig. S1.
C-myc-eNOS was purified from the lysate of c-myc-eNOS overexpressing tsA201 cells using anti-c-myc affin-
ity matrix. This purified eNOS was applied as analyte in surface plasmon resonance (SPR) based binding assays 
to assess its interaction with GST-MYPT1 (Fig. 1d) immobilized on anti-GST coupled sensor chip25. The sensor-
grams obtained at two different eNOS concentrations indicated stable interaction of MYPT1 with eNOS.
Experiments to visualize possible interactions of eNOS and MYPT1 in situ in ECs of different origin were car-
ried out using confocal microscopy. Co-localization of eNOS and MYPT1 was apparent at the perinuclear regions 
in human pulmonary artery EC (HPAEC) (Fig. 1e). Co-localization of MYPT1 and eNOS was also identified in 
bovine pulmonary artery EC (BPAEC) (Fig. 1f) at similar locations to that of HPAECs and confirmed by proxim-
ity ligation assay, too (Fig. 1g). Thus, the above data suggest that eNOS and MYPT1 interact in ECs implying that 
MP may be a possible PP1 holoenzyme candidate involved in the dephosphorylation of eNOS.
The tsA201 cells do not express eNOS, however, they are assumed to include the kinase/phosphatase 
machineries able to phosphorylate/dephosphorylate eNOS and MYPT125. Thus, tsA201 cells transfected with 
c-myc-eNOS construct appeared to be a suitable model system to assess phosphorylation/dephosphorylation of 
eNOS upon PKC activation and phosphatase inhibition by calyculin-A (CLA), a cell permeable toxin inhibitor 
of PP1 and PP2A. Figure 2a shows that in c-myc-eNOS expressing cells there is a basal level of phosphorylation 
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at Ser1179 of eNOS (eNOSpSer1179), while eNOSpThr497 is very low (Fig. 2a, upper panel). In agreement with the 
low level of the inhibitory phosphorylation (eNOSpThr497) and the occurrence of activatory phosphorylation 
(eNOSpSer1179) eNOS expressing tsA201 cells produced significant amount of NO as judged by NO measurements 
(Fig. 2b). Activation of PKC by treatment of tsA201 cells with phorbol 12-myristate-13-acetate (PMA) alone, or in 
combination with CLA, increased the level of eNOSpThr497 by ~4-fold or ~7-fold, respectively. On the other hand 
the level of eNOSpSer1179 was slightly enhanced only. PMA, or PMA plus CLA treatments suppressed dramatically 
the NO production of eNOS expressing tsA201 cells as shown on Fig. 2b. These data confirm previous suggestions 
that phosphorylation of eNOS at Thr497 is a major determinant in the regulation of eNOS activity11.
We also tested how FLAG-MYPT1 overexpression may influence eNOS activity in eNOS expressing tsA201 
cells. As seen in Fig. 2c, expressing FLAG-MYPT1 alone did not induce NO production. When c-myc-eNOS 
was expressed alone NO synthesis was observed which was significantly higher when FLAG-MYPT1 was 
co-expressed with c-myc-eNOS in tsA201 cells. These data might also implicate MYPT1 in the regulation of 
Figure 1. Interaction of eNOS with MYPT1. (a) Identification of eNOS in GST (control) or GST-MYPT1 
pull-down fractions of HUVEC lysate using glutathione-Sepharose to isolate the interacting proteins. (b,c) Co-
immunoprecipitation of overexpressed FLAG-MYPT1 and c-myc-eNOS in tsA201 cell lysates using anti-FLAG 
(b) or anti-c-myc-agarose (c) beads to isolate the protein complexes. Cropped images of representative Western 
blots are shown in (a,b) and (c). Uncropped, full-length blots are presented in Supplementary Information 
in Fig. S1. (d) Binding of eNOS to full-length GST-MYPT1 immobilized to anti-GST coupled CM5 sensor 
chips. Purified c-myc-eNOS at 0.5 or 1 μ M concentrations in running buffer (10 mM Hepes (pH 7.4), 0.15 M 
NaCl, 3 mM EDTA, and 0.005% (v/v) Surfactant P20) was injected over the GST (control) and GST-MYPT1 
surfaces at 0 time and the association phase of the interaction was monitored for 7 min. The dissociation 
phase in running buffer without c-myc-eNOS was started (at 7 min as indicated by an arrow) and recorded for 
3.5 min. The surface (with immobilized recombinant GST) was treated identically to the GST-MYPT1 surfaces 
to determine unspecific binding which was subtracted from the data obtained with the GST-MYPT1 surfaces. 
Representative sensorgram of two independent experiments are shown. (e) Co-localization of MYPT1 (green) 
and eNOS (red) in human pulmonary artery endothelial cells (HPAEC). Images were captured by confocal 
microscopy. Merged images of eNOS and MYPT1 are also shown. Scale bar, 10 μ m. (f) Co-localization of 
MYPT1 (green) and eNOS (red) in BPAECs. Images were captured by confocal microscopy and merged images 
are shown. Scale bar, 50 μ m. (g) MYPT1 and eNOS interactions were assessed by Duolink proximity ligation 
assay (PLA) as described in Materials and Methods. For the control only the secondary antibodies were added. 
Red fluorescence indicates interacting MYPT1-eNOS complexes. Scale bar, 50 μ m.
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eNOS activity and NO production. To further confirm the above data we also carried out experiments with 
eNOS knock-in HEK293 cells (HEK293-eNOS) in which FLAG-MYPT1 was overexpressed, then NO produc-
tion was measured in the absence or presence of N-nitro-L-arginine-methyl ester (L-NAME), an eNOS inhibitor 
(Fig. S2). NO production was higher in HEK293-eNOS cells compared to HEK293 cells. It was also apparent that 
FLAG-MYPT1 overexpression increased eNOS activity significantly, however, it was not due to changes either 
in eNOS expression or in the phosphorylation level of eNOSpThr497 (Fig. S2, upper panel). L-NAME suppressed 
increased eNOS activity to control level in either the untransfected or FLAG-MYPT1 transfected HEK293-eNOS 
cells (Fig. S2, lower panel).
Other posttranslational modifications of eNOS such as phosphorylation at tyrosine657 (Tyr657)26 or 
S-glutathionylation at cysteine residues27 have also been reported to decrease eNOS activity. We observed no 
differences in eNOS phosphorylation on Tyr657 in eNOS knock-in HEK293 cells, which however might be due 
to the limited specificity of the used commercial antibody for this modification (not documented). Similarly, 
the immunoprecipitated S-glutathionylated proteins from eNOS knock-in HEK293 cells were limited and 
Figure 2. Phosphorylation of eNOS in eNOS expressing tsA201 cells upon challenges with PMA, or 
PMA plus CLA. (a) Phosphorylation of eNOS at Ser1179 or at Thr497 was analysed using anti-eNOSpSer1179 
or anti-eNOSpThr497 in untreated control, and in 100 nM PMA (for 30 minutes) or 10 nM CLA plus 100 nM 
PMA (for 30 minutes) treated cells. Anti-eNOS was applied to determine eNOS as a loading control. 
Representative Western blots (upper panel) and densitometric analysis of the blots (lower panel) of three 
independent experiments are shown. (b) Effect of 100 nM PMA (for 30 minutes) or 10 nM CLA plus 100 nM 
PMA (for 30 minutes) treatments on NO production in the culture medium of eNOS overexpressing tsA201 
cells. Thirty minutes following application of the effectors NO was determined as described in Materials 
and Methods. (c) The effect of co-expression of MYPT1 and eNOS in tsA201 cells on eNOS activity and NO 
production. Approximately equal number of tsA201 cells were plated in 6 well plates and 24 hours later the 
cells were transfected with pM11-FLAG-MYPT1 and/or pcDNA3.1c-myc-eNOS. 48 hours after transfection 
NO was determined in the culture medium. Data represent means ± SEM (n = 3), n.s.: not significant, 
*p  < 0.05, **p < 0.01, ***p < 0.001, One-way ANOVA, Newman-Keuls post-hoc testing. Cropped images 
of representative Western blots are shown in (a) and (c). Uncropped, full-length blots are presented in 
Supplementary Information in Fig. S8.
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among them eNOS was not identified. Based on these results we conclude that Tyr657 phosphorylation or 
S-glutathionylation plays no role in the regulation of eNOS activity in our cell culture model.
Identification of MP as an eNOSpThr497 phosphatase. C-myc-eNOS was expressed in tsA201 cells 
and isolated on anti-c-myc-Sepharose, then the matrix-bound eNOS was phosphorylated by ROCK at Thr497 
(Fig. 3a) in the presence of microcystin-LR (PP1 and PP2A inhibitor). After washing the anti-c-myc-Sepharose 
bound phosphorylated eNOS to remove ATP, Mg2+ and microcystin-LR, the mixture was divided into four equal 
aliquots and beside control (incubated with assay buffer only) they were subjected to addition of FLAG-MYPT1, 
PP1c and PP1c plus FLAG-MYPT1. It is shown that FLAG-MYPT1 was without effect, while PP1c alone 
dephosphorylated eNOSpThr497 to a relatively low extent, which was significantly increased when both PP1c and 
FLAG-MYPT1 were present (Fig. 3a and b). These results suggest that MP holoenzyme (i.e. the PP1c-MYPT1 
complex) is an eNOSpThr497 phosphatase, and since MYPT1 enhances the phosphatase activity of PP1c on 
eNOSpThr497 it fulfils a targeting and activating role in this dephosphorylation process.
To confirm further the role of PP1c and MYPT1 in the dephosphorylation of eNOSpThr497 silencing of these 
proteins in BPAECs with siRNAs were carried out and in parallel the level of eNOSpThr497 was also determined. 
PP1c was silenced with siRNA specific for all isoform (PP1cα , PP1cβ /δ , PP1cγ 1), however decrease in the level of 
PP1cδ was assessed as this isoform was identified to associate with MYPT1specifically in cells28. It is apparent on 
Fig. 4 (upper panel) that silencing either PP1cδ or MYPT1, or both, led to decreased expression of these proteins 
(see Fig. S3 for the statistics of silencing efficiency) which was accompanied by an increase in the level of eNO-
SpThr497 (Fig. 4, upper and lower panels) implicating both subunits of MP holoenzyme in the dephosphorylation 
of this phosphorylated residue.
The effects of PKC activation and phosphatase inhibition on the inhibitory phosphorylation 
of eNOS and MYPT1. We challenged BPAECs with 10 nM calyculin-A (CLA) or 1 μ M tautomycin (TM) 
to inhibit PP2A and PP1, respectively. CLA and TM inhibit both PP2A and PP1 in in vitro phosphatase assays 
and there are also controversies concerning their selectivity in cellular systems29,30. However, our recent results31 
confirmed that CLA (up to 50 nM) caused partial, but predominant inhibition of PP2A, while TM (up to 1 μ M) 
primarily suppressed PP1 in THP-1 cells. Figure 5a illustrates that treatment of BPAECs with CLA alone resulted 
in a dramatic increase in the phosphorylation of MYPT1 at Thr696 (MYPT1pThr696) while TM and PMA did not 
Figure 3. Myosin phosphatase dephosphorylates eNOS at the inhibitory phosphorylation site, (pThr497): 
the role of PP1c and MYPT1 in the dephosphorylation of eNOSpThr497. (a) c-myc-eNOS was isolated from 
the lysate of c-myc-eNOS expressing tsA201 cells on anti-c-myc-agarose beads and was phosphorylated by 
Rho-kinase (ROCK) for 60 minutes as described in Materials and Methods. Then, the resin was separated 
into four equal parts. Phosphorylated c-myc-eNOS was subjected to dephosphorylation for 15 min by FLAG-
MYPT1 alone, PP1c alone, or by a mixture of PP1c and FLAG-MYPT1. The relative level of eNOSpT497 on 
anti- eNOSpT497 developed blots after phosphorylation by ROCK but before addition of the phosphatase 
components was considered as control (100%). Cropped images of representative Western blots are shown in 
(a). Uncropped, full-length blots are presented in Supplementary Information in Fig. S8. Densitometric analysis 
(b) of blots from three independent experiments are shown (means ± SEM (n = 3), *p < 0.05, **p < 0.01, One-
way ANOVA, Newman-Keuls post-hoc testing).
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increase significantly the level of MYPT1pThr696. Figure 5b illustrates that enhanced level of eNOSpThr497 paral-
leled with the increase of the inhibitory phosphorylation of MP in MYPT1 (MYPT1pThr696). In contrast, TM 
increased the level of eNOSpThr497 slightly, but not significantly. Activation of PKC by PMA also increased the 
level of eNOSpThr497 in accordance with results shown earlier for eNOS expressing tsA201 cells (see Fig. 2a). As 
PP2A is assumed to dephosphorylate MYPT1pThr696, the above data support the scenario that PP2A specific inhi-
bition increased the level of MYPT1pThr696 resulting in inhibition of MP and suppression of eNOS activity as a 
consequence of increase in eNOSpThr497. We determined the distribution of the activity of PP1 and PP2A in the 
lysates of untreated or CLA treated BPAECs using inhibitor-2 (I2) to specifically inhibit PP1 and attempted also 
to identify type specific inhibition by CLA (Fig. 5c). It is seen that ~65% of the total phosphatase activity was due 
to PP1 while PP2A (the activity measured in the presence of I2) represented ~35%. CLA decreased the phos-
phatase activity of the lysate by ~25%, and a large portion (~20%) of this inhibitory impact was exerted on the I2 
suppressed (i.e. PP2A) activity indicating predominant inhibition of PP2A by CLA in accord with our previous 
findings31 in THP-1 cells.
The above data are consistent with a dephosphorylation sequence of PP2A → MYPT1pThr696-PP1c → eNO-
SpThr497, but this putative mechanism requires further experimental confirmation. Therefore, activation of PP2A 
in BPAECs and subsequent dephosphorylation of both MYPT1pThr696 and eNOSpThr497 were probed. It was previ-
ously shown that in melanoma cells EGCG binds to the 67LR32 and increases PP2A activity33 in a protein kinase 
A (PKA) dependent manner. This activation of PP2A was shown earlier to be specific for the PP2A trimer holo-
enzyme including the Bδ subunit and was due to phosphorylation of Bδ by protein kinase A (PKA)34. Both 67LR 
and PP2A-Bδ (see Fig. S4) as well as PKA (see Fig. 6c) are present in BPAECs, therefore activation of PP2A with 
Figure 4. Effect of silencing of PP1c, MYPT1, or both PP1c and MYPT1 by siRNAs on the level of 
eNOSpThr497. BPAECs were transfected with nonspecific (scrambled) siRNA (control), or with siRNA-PP1, 
siRNA-MYPT1 and with a mixture of siRNA-PP1 and siRNA-MYPT1. The changes of PP1cδ and MYPT1 
protein levels, as well as the level of eNOSpThr497 was determined by Western blotting. Cropped images 
of representative Western blots are shown (upper panel). Uncropped, full-length blots are presented in 
Supplementary Information in Fig. S8. The bar graph represents the change in the level of eNOSpThr497 compared 
to the control. Densitometric analysis of blots from at least four independent experiments (lower panel) are 
shown (means ± SEM, *p < 0.05, One-way ANOVA, Newman-Keuls post-hoc testing).
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Figure 5. The effect of PKC activation and phosphatase inhibition on the level of MYPT1pThr696 and 
eNOSpThr497. BPAECs cells were treated with 10 nM CLA, 1 μ M TM or 100 nM PMA for 30 min and the level 
of MYPT1pThr696 (a) and eNOSpThr497 (b) was monitored by Western blotting (upper panel) and quantified 
by densitometry (bar graphs). Cropped images of representative Western blots are shown in (a) and (b). 
Uncropped, full-length blots are presented in Supplementary Information in Fig. S8. Densitometric analysis 
of blots from 3–4 independent experiments was carried out (means ± SEM, n.s.: not significant, *p < 0.05, 
**p < 0.01, ***p < 0.001, compared to control. One-way ANOVA, Newman-Keuls post-hoc testing). (c) BPAECs 
cells were treated with 10 nM CLA and the phosphatase activity in the lysates of untreated (control) or CLA 
treated cells was determined in the absence or the presence of 2 μ M inhibitor-2 using 32P-MLC20 as substrate. 
Data represent means ± SEM, **p < 0.01 (n = 3), One-way ANOVA, Newman-Keuls post-hoc testing.
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Figure 6. The effect of EGCG treatment and PKA silencing on the level of MYPT1pThr696, eNOSpThr497 and 
ppMLC20Thr18/Ser19. (a) BPAECs were pretreated with 100 nM PMA for 30 minutes, then challenged with EGCG 
in the indicated concentrations for 1 hour. Changes in the level of MYPT1pThr696, eNOSpThr497 and ppMLC20 
were assessed by Western blotting with phospho-specific antibodies upon the different challenges (upper 
panel). Cropped images of representative Western blots are shown. Uncropped, full-length blots are presented 
in Supplementary Information in Fig. S8. Bar graphs represent the changes in the level of MYPT1pThr696 (upper 
graph), eNOSpThr497 (middle graph) and ppMLC20 (lower graph) determined by densitometric analysis of blots 
from 3–4 independent experiments (means ± SEM, n.s.: not significant, *p < 0.05, **p < 0.01, ***p < 0.001 
compared to control, i.e. without EGCG, One-way ANOVA, Newman-Keuls post-hoc testing). (b) BPAECs 
cells were treated with 20 μ M EGCG and the phosphatase activity in the lysates of untreated (control) or EGCG 
treated cells was determined using 32P-MLC20 as substrate. Data represent means ± SEM (n = 3), two-tailed 
Student’s t-test. (c) BPAECs were transfected with scrambled or PKA catalytic subunit (PKAc) specific siRNA 
then treated with PMA and EGCG and the changes in the level of MYPT1pThr696, eNOSpThr497 and ppMLC20 
were assessed as described in (a).
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EGCG was attempted. Since the endogenous level of eNOSpThr497 in BPAECs was quite low, we treated the cells 
with PMA to achive a higher level of eNOSpThr497 in order to detect more reliably eNOSpThr497 dephosphorylation. 
Treatment of BPAECs with EGCG in a concentration range from 1 μ M to 20 μ M resulted in substantial decrease 
in the levels of both MYPT1pThr696 (Fig. 6a, upper panel and upper bar graph) and eNOSpThr497 (Fig. 6a, upper 
panel and middle bar graph), suggesting that PP2A is involved in their dephosphorylation. Presumably, PP2A 
induces activation of MP via dephosphorylation of MYPT1pThr696 resulting in subsequent dephosphorylation and 
activation of eNOS as well. Moreover, EGCG also induced substantial dephosphorylation of 20 kDa light chain 
of myosin II (MLC20) as assessed by an antibody specific for diphosphorylated MLC20 (ppMLC20) as shown in 
Fig. 6a (upper panel and lower bar graph). In accordance with the above assumptions Fig. 6b demonstrates that 
EGCG treatment of BPAECs significantly increased the phosphatase activity. It is to note that EGCG has been 
shown to increase the phosphorylation level at Ser1179 of eNOS, a phosphosite which is known to stimulate 
eNOS activity35–37. We found that under our experimental conditions (i.e. when BPAECs were pretreated with 
PMA) there was a substantial basal phosphorylation level at Ser1179 of eNOS and a slight increase upon EGCG 
treatment was observed only at 5 μ M EGCG (Fig. S5).
Next, we searched for further evidence for the PKA dependence of the EGCG induced dephosphorylation 
processes. We silenced the catalytic subunit α of PKA (PKAcα ) in BPAECs and assessed the level of MYPT1pThr696, 
eNOSpThr497 and ppMLC20 in the cells. Silencing efficacy and statistics are shown in Fig. S6. Figure 6c illustrates 
the changes in the level of MYPT1pThr696, eNOSpThr497 and ppMLC20 in BPAECs transfected with scrambled or 
PKAcα specific siRNAs and then challenged with different concentration of EGCG. It is apparent that trans-
fection of BPAECs with scrambled siRNA resulted in similar patterns of dephosphorylation of MYPT1pThr696, 
eNOSpThr497 and ppMLC20 upon EGCG treatments as observed in Fig. 6a. In BPAECs transfected with PKAcα 
specific siRNAs a slight decrease in the basal phosphorylation of MYPT1pThr696, eNOSpThr497 and ppMLC20 was 
observed, however, no significant dephosphorylation of these proteins were detected upon challenges by EGCG. 
These data confirmed that EGCG induced phosphatase activation in BPAECs is also accomplished in a PKA 
dependent manner.
The effects of PKC activation and phosphatase inhibition/activation on NO production and 
transendothelial electrical resistance of BPAECs. The effect of PKC activation as well as phosphatase 
inhibition/activation was also assayed on physiological responses of BPAECs such as NO production and barrier 
function. The latter was characterized by measuring transendothelial electrical resistance (TER) (Fig. 7c and d). 
For NO measurement NO specific 4,5-diaminofluorescein diacetate (DAF-2 DA) fluorescence of cells was 
captured (Fig. 7a). BPAECs loaded with the reaction mixture including DAF-2 DA were subjected to differ-
ent treatments, then fluorescent intensities of cells were determined (Fig. 7b). It is seen that PMA moderately, 
but significantly decreased NO synthesis. In contrast, EGCG spectacularly enhanced NO production and it also 
attenuated PMA suppressed NO synthesis. These changes in NO synthesis appear to correlate well with how these 
effectors influenced the level of eNOSpThr497 (see Figs 5 and 6a,b). It was also established that the increase in NO of 
BPAECs challenged by either acetylcholine or EGCG was profoundly inhibited when the cells were preincubated 
with L-NAME (Fig. S7).
In another set of experiments we investigated how PMA, CLA, TM, EGCG and the combination of PMA and 
EGCG affect TER of BPAECs. PMA and TM suppressed TER moderately and the decreasing tendency in TER 
appeared to be partially reversible in case of PMA, but irreversible with TM during the assay period (Fig. 7c). CLA 
also induced a fast and dramatic decrease in TER in an irreversible manner. In accord with our earlier findings25 
this “acute” effect of the phosphatase inhibitors on TER was presumably due to the inhibition of MP resulting in 
sustained phosphorylation of MLC20 which contributes highly to decreasing TER. In contrast, EGCG enhanced 
TER of BPAECs and attenuated suppression of TER by PMA either when it was added together or 30 min after 
PMA (Fig. 7d). These data suggest that PKC activation or phosphatase inhibition suppress TER compromising 
barrier function of BPAECs. On the other hand, phosphatase activation by EGCG appears to improve barrier 
function and helps to restore, at least in part, the effect of barrier suppressing agents.
Discussion
Phosphorylation/dephosporylation of eNOS at Thr497 is a crucial factor in the mediation of eNOS activity and 
it is also involved in balancing whether eNOS generates NO or superoxide20. PKC and ROCK are the kinase 
candidates to target Thr497 under physiological conditions19, while the dephosphorylating phosphatase is not 
unambiguously identified. There appears to be a consensus in the literature that PP1 type phosphatase acts on 
phosphorylated Thr497 in eNOS (eNOSpThr497) in ECs10,11,21. Surprisingly, the type of PP1 holoenzyme has not 
been identified yet, although this knowledge is essential to uncover physiological regulatory events in the dephos-
phorylation of eNOSpThr497. Our present study identifies myosin phosphatase (MP), consisting of associated PP1cδ 
and MYPT1, as the phosphatase holoenzyme which dephosphorylates eNOSpThr497. This claim is supported by 
the following experimental data: (i) MYPT1 and eNOS co-precipitated from the lysates of HUVEC, HPAEC 
and BPAEC and their colocalization was also apparent in these ECs (see Fig. 1) (ii) SPR-based binding assays 
using purified proteins also confirmed stable interaction between c-myc-eNOS and GST-MYPT1 (iii) the PP1δ – 
MYPT1 complex dephosphorylated eNOSpThr497 effectively in which MYPT1 had a targeting role increasing the 
activity of PP1cδ toward eNOSpThr497 (see Fig. 3) (iv) silencing PP1δ , MYPT1 or both in BPAECs increased the 
level of eNOSpThr497 (see Fig. 4). We also provide evidence that overexpression of MYPT1 in eNOS expressing 
tsA201 cells or in eNOS knock-in HEK293 cells increased eNOS activity without changing the expression level 
of eNOS. This activation of eNOS could not be due to changes in eNOSpThr497 dephosphorylation either as in 
HEK293-eNOS cells eNOSpThr497 was quite low and did not change upon FLAG-MYPT1 overexpression (see 
Fig. S2, upper panel). We speculate that the stable interaction between MYPT1 and eNOS might influence intra-
cellular localization of eNOS which could also affect enzyme activity3. It is to note, however, that in light of a 
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recent report38 MYPT1 may also have an influence on eNOS expression as in basilar arteries of old, heterozy-
gous MYPT1-Thr696Ala knock-in mice eNOS-mRNA was lower in knock-in compared to the wild-type animal. 
Experiments with this MYPT1-Thr696Ala knock-in mice also established the role of the phosphorylation of 
MYPT1Thr696 in the increased basal tone of basilar arteries. In summary, our present data implicates MP in the 
activation of eNOS accompanied by enhanced NO production in ECs. Thus, application of this regulatory sce-
nario to smooth muscle tissues would imply that the NO diffused from ECs to smooth muscle cells may induce 
MP activation and relaxation of smooth muscles. Indeed, it was previously reported39 that the NO donor sodium 
nitroprusside (SNP) caused relaxation of histamine-contracted carotid media concurrent with activation of MP 
and with declined phosphorylation level of both MLC20 and the C-kinase activated phosphatase inhibitor of 
17 kDa (CPI17), a phosphorylation dependent MP specific inhibitor protein. Moreover, SNP treatment triggered, 
beside a rapid dephosphorylation of CPI-17, a slow dephosphorylation of MYPT1 (both at phospho-Thr696 and 
phospho-Thr853) in denuded femoral artery suggesting an NO induced biphasic reactivation of MP by dephos-
phorylation during smooth muscle relaxation40. The extent of relaxation of precontracted arterial smooth mus-
cle induced by endogenous NO released from the endothelium was similar to that of found with SNP treated 
denuded artery establishing the physiological significance and relevance of the above dephosphorylation pro-
cesses in the mechanism of smooth muscle relaxation.
Figure 7. Effect of PKC activation and phosphatase inhibition/activation on NO production and the 
transendothelial electrical resistance (TER) of BPAECs. (a) BPAECs were grown on coverslips in serum free 
medium and loaded with the reaction mixture including DAF-2 DA for 60 min. Next, coverslips were incubated 
with the PKC activator PMA (100 nM), EGCG (20 μ M) and the combination of PMA and EGCG in parallel with 
the non-treated coverslips (control) for 60 min. Scale bar, 50 μ m. (b) Single cell fluorescence activity determined 
by ImageJ after different treatments indicated in (a). Results of single cell values (120–153 individual cells) 
of two independent experiments are shown in means ± SEM. (n.s.: not significant, ***p < 0.001, One-way 
ANOVA, Newman-Keuls post-hoc testing). (c) BPAECs grown in serum free medium in ECIS arrays were 
untreated (control), or treated with PMA (100 nM), 10 nM CLA or with 1 μ M tautomycin (TM) for 30 minutes. 
(d) BPAECs cells grown on ECIS arrays were treated with vehicle, 20 μ M EGCG, 100 nM PMA or with 100 nM 
PMA and 20 μ M EGCG, added together or EGCG was added 30 minutes after PMA. Time points of treatment 
with effectors are indicated by arrows. Normalized TER values were expressed as mean ± SEM of 3–4 individual 
experiments.
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It has been established that regulation of MP activity occurs via inhibitors (toxins, inhibitory proteins) inter-
acting with PP1cδ 22,23,31 and/or by inhibitory phosphorylation of MYPT1 at Thr696 and Thr850 residues41. In this 
study regulation of eNOSpThr497 level by MP was modelled using cell permeable phosphatase inhibitory toxins 
(CLA and TM) at concentrations assumed to be specific for PP1 and PP2A29–31. It should be emphasized that the 
viability of ECs limits the applied toxin concentrations, therefore, only partial inhibition of PP2A or PP1 by these 
toxins could be assumed as we showed previously31. Our present data demonstrate that PP1 specific inhibition 
by TM increased eNOSpThr497 and MYPT1pThr696 moderately. In contrast, CLA enhanced both eNOSpThr497 and 
MYPT1pThr696 more profoundly via predominant inhibition of PP2A as validated by phosphatase assays of BPAEC 
lysates (Fig. 5b). These results are in accordance with previous findings demonstrating that inhibition of PP2A41 
or PP2B25, enzymes which dephosphorylate MYPT1pThr696, leads to increased level of MYPT1pThr696. The latter is 
accompanied by MP inhibition and as a consequence enhanced phosphorylation level of MLC20, a dedicated 
substrate of MP. The above data establish a mechanism implying an interplay of PP2A and MP in the regulation of 
eNOSpThr497 dephosphorylation, however, the physiological significance of these events await further clarification.
Previous work10 has shown that forskolin treatment of ECs stimulated dephosphorylation of eNOSpThr497 by 
PP1, suggesting the involvement of a signalling pathway via cAMP/PKA in PP1 activation, however, the detailed 
mechanism has not been elucidated. Our present results highlight another signalling mechanism for physio-
logical stimulation of eNOSpThr497 dephosphorylation (see Fig. 8). This involves EGCG, a green tea polyphenol 
as an agonist interacting with 67LR and signalling downstream to activate PKA and PP2A. It has been proven 
in melanoma cell lines that EGCG stimulates the activity of PP2A via the 67LR in a cAMP/PKA-dependent 
manner and this activated PP2A dephosphorylated both phosphorylated CPI-17 and MYPT1pThr696 resulting 
in MP activation and dephosphorylation of merlin, another MP substrate33. Here, we confirmed that the major 
elements (67LR, PKA and PP2A-Bδ ) required for this signalling are present in BPAECs (see Fig. S4), therefore, 
it is reasonable to assume that the EGCG → 67LR → PKA → PP2A pathway also operates in ECs and induces 
PP2A activation. It is apparent that PP2A activated along this pathway results in marked dephosphorylation of 
MYPT1pThr696 coupled with activation of MP (see Fig. 6) and subsequent dephosphorylation of eNOSpThr497 and 
ppMLC20 in ECs. The other side of the EGCG signalling is that it also results in increased level of phosphoryla-
tion at Ser1179 in eNOS (eNOSpSer1179)35–37 via the activation of PKA/phosphatidylinositol 3-kinase (PI3K)/pro-
tein kinase B (Akt) pathway35 and src-kinase36. In accordance with these findings EGCG also increased slightly 
the level of eNOSpSer1179 under our experimental conditions (Fig. 5S). Thus, the above data establish a physiolog-
ically relevant signalling pathway for the previously described reciprocal phosphorylation10,11,15 of eNOS at the 
inhibitory Thr497 and the activatory Ser1179 residues. Our present data support the existence of a novel pathway 
via EGCG → 67LR → PKA → PP2A → MP activation for effective dephosphorylation of both eNOSpThr497 and 
ppMLC20 (see Fig. 8).
Figure 8. Regulation of eNOS activity and endothelial barrier function by phosphorylation-
dephosphorylation. We have shown that myosin phosphatase (MP) interacts with eNOS via its myosin 
phosphatase target subunit-1 (MYPT1) which directs protein phosphatase-1 catalytic subunit (PP1c) for 
dephosphorylation of phospho-Thr497 allowing binding of Ca2+-calmodulin (CaM) and activation of eNOS. 
PMA and/or calyculin-A (CLA) increases the phosphorylation level of eNOS-Thr497 by activation of protein 
kinase C (PKC) and/or inhibition of PP2A, respectively (red lines). Suppression of PP2A activity results in 
increased phosphorylation of MYPT1 at Thr696 and inhibition of MP. Both PKC activation and MP inhibition 
contributes to the inactivation of eNOS via increased phosphorylation at Thr497 and thus interfering with 
CaM binding. Inactivation of eNOS accompanies by decreased NO production while the enhanced LC20 
phosphorylation leads to increased contractility and thereby endothelial barrier dysfunction. Our present 
data suggest that the reactivation of eNOS and dephosphorylation of LC20 may be accomplished by an EGCG 
induced activation of both PP2A and MP involving the 67 kDa laminin receptor (67LR) and protein kinase A 
(PKA) in this phosphatase activation. The 67LR mediated action of EGCG implies activation of PKA which 
phosphorylates the Bδ subunit of PP2A resulting in PP2A activation and subsequent dephosphorylation of 
MYPT1 (at phospho-Thr696) and activation of MP (green lines). Then, the activated MP dephosphorylates 
both phosho-Thr497 in eNOS and phospho-Thr18/Ser19 in LC20 resulting in increased NO production and 
decreased contractility (relaxation) with endothelial barrier enhancement.
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EGCG and structurally related other catechins may have a plethora of intracellular targets and they may exert 
distinct physiological influences. In our previous work we showed that EGCG interacted with and inhibited PP1c 
activity at micromolar concentrations in in vitro phosphatase assays and binding of EGCG to the hydrophobic 
groove of the PP1c substrate binding region was also established42. However, only moderate extent of phosphatase 
inhibition occurred when intact cells were incubated with relatively high EGCG concentration (100–500 μ M) 
and it was presumably due to low extent of EGCG permeation through the cell membranes43. These data suggest 
distinct mechanism of actions of EGCG on cells depending upon its applied concentrations. Thus, at low con-
centration (1–20 μ M) EGCG exerts its effect through binding to 67LR initiating a signalling pathway leading to 
phosphatase activation. In contrast, at high concentration EGCG might also permeate cells to certain extent and 
binds to PP1c causing phosphatase inhibition. However, regarding the assumed EGCG concentration (~1 μ M) 
after regular green tea consumption only the former process (EGCG → 67LR signalling) might have physiolog-
ical relevance. Another issue is if other catechins structurally related to EGCG may exert similar effects on ECs. 
A study by Lorenz et al.37 reported that several catechins (epicatechin, epigallocatechin, epicatechin-3-gallate) 
which include structurally similar units present in EGCG were without significant effect on eNOS activity and 
NO production. On the contrary, Ramirez-Sanchez et al.44 demonstrated that (-)-epicatechin (EPI) activated 
eNOS and NO production in a stereospecific and Ca2+-independent manner in ECs. EPI enhanced the level of 
eNOSpSer1179 in accordance of its eNOS activating feature. However, with respect to its effect on eNOSpThr497 level 
controversial data have been published as upon EPI addition both decreased45 and unchanged44 level of eNO-
SpThr497 was reported. It has been suggested that EPI may exert its physiological effects via the pathway involving 
phosphatidylinositol 3-kinase (PI3K)44. However, it still remains to be elucidated if EPI acts via the same path-
way(s) on ECs as does EGCG.
In agreement with previous studies46,47 we found that PKC activation by PMA, or phosphatase inhibition with 
CLA, caused decrease in TER of EC monolayers. The TER and NO suppressing effect of PMA was attenuated by 
EGCG which helped to restore, at least partially, barrier integrity and eNOS activity. There are apparent contro-
versies with respect to how changes in NO level influence endothelial permeability (reviewed by Durán et al.2). It 
appears that hyperpermeability induced by inflammatory agents requires eNOS activation and increased NO pro-
duction48. In contrast, our present findings are consistent with the conclusions that EGCG induced enhancement 
of NO is accompanied by stabilization and improvement of endothelial barrier function. These contradictory 
findings might be due to widespread influences of EGCG on the signalling pathways in ECs. On one hand, EGCG 
may also stimulate phosphorylation of Ser1179 in eNOS that is required to enhanced eNOS activity in ECs35–37 
via a pathway distinct from that of operates during phosphatase activation. On the other hand, EGCG induced 
phosphatase activation is not limited only for enhanced dephosphorylation and stimulation of eNOS, but it also 
has a “relaxing” effect on the contractile machinery of ECs by inducing ppMLC20 dephosphorylation (see Fig. 6a 
and b) decreasing the amount of stress fibres and restoring gap formation between the cells. These events may 
also lead to decreased permeability and as a consequence barrier improvement of ECs. Moreover, this EGCG 
induced increase of NO was also observed in rat aortic rings35 or mesenteric vascular beds36 causing a dose- and 
endothelium dependent vasorelaxation of these smooth muscles. This vasodilation was suppressed by L-NAME 
indicating the direct role of eNOS in these events.
In summary, our present study contributes to the understanding of the regulation of eNOS activity in EC from 
an angle less frequently studied so far. Activation of eNOS requires dephosphorylation of eNOSpThr497, therefore, 
identification of the phosphatase involved may shed light on novel regulatory pathways. We have shown here 
that MP (the complex of PP1c and MYPT1) dephosphorylates eNOSpThr497 and the inhibitory phosphorylation 
of MYPT1 at Thr696 is a major regulatory event in eNOS dephosphorylation. The pathways regulating inhibi-
tory MYPT1 phosphorylation have been described22,23, and among these signalling via RhoA/ROCK is involved 
in the phosphorylation of both Thr696 in MYPT125 and Thr497 in eNOS12 in BPAECs. Thus, ROCK can act 
in a concerted manner on the phosphorylation/dephosphorylation of eNOS: it may phosphorylate Thr497 in 
eNOS49 and Thr696 in MYPT1 simultaneously leading to a sustained level of eNOSpThr497 and suppression of NO 
production. Another novel aspect of our present findings is that we identify a signalling pathway in ECs which 
operates via interaction of EGCG with 67LR leading to PP2A-driven activation of MP which accompanies with 
dephosphorylation (and activation) of eNOS and ppMLC20 (see Fig. 8). In addition to increasing eNOS activity 
and NO production EGCG also improves endothelial barrier function. It has been established that mono- and 
diphosphorylation of MLC20 is involved in the fine tuning of barrier disruption in ECs50. EGCG, by stimulating 
ppMLC20 dephosphorylation decreases the contractility of ECs thereby restoring and improving barrier func-
tion. Moreover, the NO synthesized in ECs plays crucial roles in the regulation of distinct cardiovascular events, 
therefore, uncovering the molecular background of the mediation of NO production may also have relevance 
with regards of cardiovascular pharmacology.
Materials and Methods
Materials. Anti-MYPT11–296 (Lontay et al.)51, rabbit skeletal muscle PP1c and 32P-MLC20 (Tóth et al.)52 were 
prepared and characterized as described previously in the respective references. All other materials were obtained 
from commercial sources and given in Supplementary Information.
Cell cultures. Umbilical cords were collected from the local hospital (Department of Obstretrics and 
Gynecology, University of Debrecen) during normal deliveries with informed consent given and the procedure 
was performed by the approval of the Ethics Committee of the University of Debrecen (Ref. number: 2909-
2008) conform the Declaration of Helsinki. Human umbilical vein endothelial cells (HUVEC) were isolated as 
previously described (Palatka et al.)53. Cells were maintained in M199 media supplemented with 20% (v/v) fetal 
bovine serum (FBS), 10 mM HEPES, 2 mM L-glutamine, 0.25 μ g/ml amphotericin B, 100 U/ml penicillin, 100 μ g/
ml streptomycin. Cells were cultured from the same batch and used at passages 4–7 for all experiments.
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Bovine pulmonary artery endothelial cells (BPAEC) (cell culture line-CCL 209) were obtained frozen at 
passage 8 (American Type Tissue Culture Collection Rockville, MD, USA), and were used between passages 
17–23. Cells were cultured in Minimum Essential Medium (MEM) supplemented with 10% (v/v) heat inac-
tivated FBS, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids solution, 2 mM glutamine, 1% (v/v) 
antibiotic-antimycotic solution. Human pulmonary artery endothelial cells (HPAEC) were purchased from 
Clonetics (San Diego, CA, USA) were cultured in EBM-2 supplemented with 10% (v/v) FBS, 0.2 ml of hydrocor-
tisone, 2 ml of human FGF-B, 0.5 ml of VEGF, 0.5 ml of long-arm insulin-like growth factor-1 (R3-IGF-1), 0.5 ml 
of ascorbic acid, 0.5 ml of human epidermal growth factor (EGF), 0.5 ml of GA-1000, and 0.5 ml of heparin solu-
tions. Cells were cultured from the same batch and used at passages 4–7 for all experiments (Kolozsvári et al.)25.
tsA201 (Health Protection Agency Culture Collection, Salisbury, UK), eNOS knock-in HEK293 cells (a kind 
gift of Dr. David Fulton, Augusta University, Augusta, GA, USA) and HEK293 cells (American Type Tissue 
Culture Collection Rockville, MD, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% (v/v) FBS, 2 mM L-glutamine, and 1% (v/v) antibiotic-antimycotic solution. Cells were main-
tained at 37 °C in a humidified atmosphere of 5% CO2.
Immunoblotting. Preparation of the samples was as follows. After phosphatase inhibitor treatment the 
cells were lysed in 0.1% (v/v) Triton X-100,150 mM NaCl, 50 mM Tris–HCl (pH 7.4), 20 mM EDTA and 0.5% 
(v/v) protease inhibitor mix containing lysis buffer. For immunoprecipitation and pull-down assays the cells 
were lysed in 0.1% (v/v) Triton X-100, 150 mM NaCl, 50 mM Tris–HCl (pH 7.4), 20 mM EDTA and 0.5% (v/v) 
protease inhibitor mix containing buffer. All of the samples were boiled for 10 minutes at 100 °C in SDS sample 
buffer in a final concentration of 62.5 mM Tris-HCl (pH 6.8), 2% (m/v) SDS, 10% (v/v) glycerol 50 mM DTT, 
0.01% (m/v) bromphenol blue, 0.5% (v/v) protease inhibitor cocktail and applied for Western blotting. Protein 
samples were separated by 10% SDS-PAGE and transferred to a 0.45 μ M pore size nitrocellulose membrane at 
100 V for 1.5 h. The membranes were blocked with 5% (m/v) nonfat dry-milk powder solution in phosphate 
buffered saline consisting of 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4 (PBS) plus 
0.1% (v/v) Tween20 (PBST), or alternatively in Tris-buffered saline consisting of 50 mM Tris–HCl (pH 7.4), 
150 mM NaCl (TBS) plus 0.1% (v/v) Tween 20 (TBST) when phospho-specific antibodies were used. During 
Western blotting the membranes were incubated for 3 hours at room temperature with the following antibodies 
at the indicated dilutions:mouse monoclonal anti-eNOS (1:2000), rabbit polyclonal anti-MYPT1 (1:1000), rab-
bit polyclonal-anti-GST (1:1000), rabbit polyclonal anti-MYPT1pT696 (1:1000), rabbit polyclonal anti-eNOSpT497 
(1:1000), rabbit polyclonal anti-eNOSpS1179 (1:1000), rabbit polyclonal anti-MLC20ppT18/S19, mouse monoclonal 
anti-β -tubulin (1:2000), rabbit polyclonal anti-PP1cδ (1:1000), rabbit polyclonal anti-PKAcα (1:1000), mouse 
monoclonal anti-67LR (1:1000), rabbit polyclonal anti-eNOSpY657/nNOSpY895 antibody (1:1000), mouse mon-
oclonal anti-glutathion antibody (1:1000) and rabbit polyclonal anti-PP2A-B56δ (1:1000). After incubation 
with the primary antibodies the membranes were washed three times with PBST or TBST and incubated with 
horseradish-peroxidase (HRP) conjugated goat polyclonal anti-rabbit- or rabbit polyclonal anti-mouse antibody 
(1:4000). Immunoreactive proteins were developed with enhanced chemiluminescence (ECL) based detection 
system. The signals were detected either with FluorChem AIC system (Alpha Innotec, San Jose, CA, USA) or 
on autoradiography films. Representative images of the Western blots were cropped from the whole blot images 
by Adobe Photosop CS5 software (Adobe Systems Inc., San Jose, CA, USA). Uncropped images of the Western 
blots are shown in Supplementary Information (Figures S1 and S8). For densitometric analysis ImageJ software 
(Research Services Branch, National Institute of Health (Bethesda, MD, USA) was used.
Transfection and gene silencing. In order to overexpress MYPT1 and/or eNOS, tsA201 cells were 
transfected with pcDNA3.1c-myc-eNOS alone, pM11-FLAG-MYPT1 alone or co-transfected with both pcD-
NA3.1-myc-eNOS and pM11-FLAG-MYPT1 expression vectors, using jetPEI transfection reagent according 
to the description of the manufacturer. Human embryonic kidney derived tsA201 cells were plated in 6-well 
plates and at 70–80% confluence were incubated with DNA/jetPEI complex. In 100 μ l serum free medium, 3 μ g 
DNA and 12 μ l jetPEI was mixed then the diluted transfection reagent was added to the DNA. The mixture was 
incubated at room temperature for 30 min and added to the cells on 6 well plates with 1.8 ml complete medium. 
After 48 h incubation the medium was collected for nitrite/NO measurement and the cells were lysed in 100 μ 
l lysis buffer (1% (v/v) Triton X-100, 150 mM NaCl, 50 mM Tris–HCl (pH 7.4), 0.1% (m/v) SDS, 1% (m/v) 
Na-deoxycholate, 20 mM EDTA and 0.5% (v/v) protease inhibitor mix), then boiled with SDS sample buffer and 
applied for immunoblot analysis. In parallel experiments the media was replaced with fresh media for treatment 
with agonist and then collected for nitrite measurement. Overexpression of eNOS and MYPT1 was assessed in 
whole cell lysate by immunoblot analysis. BPAE cells seeded on 6 well plates were transfected with non-specific 
(scrambled) or pan PP1c, or MYPT1 specific siRNA duplexes in 20 nM final concentration using DharmaFect 
2 transfection reagent. Transfection reagent and different siRNAs were diluted is serum free media in separate 
tubes. After 5 minutes of incubation at room temperature diluted transfection reagent was added to the diluted 
siRNA, followed by incubation at room temperature for 20 minutes. When the transfection complex was formed, 
the transfection mixture was added to BPAECs in serum free media. After 6 hours incubation FBS was supple-
mented to the cell cultures in 20% of final concentration, followed by 48 h further incubation. The transfected cells 
were washed once with ice-cold PBS, lysed in 100 μ l lysis buffer and used for Western blotting.
Nitric-oxide measurement. NO-content of the cell culture medium was determined by Sievers NO 
Analyzer NOA 280i (Sievers Instruments Inc., Boulder, CO) according to the manufacturer’s instructions. After 
30 minutes or 48 hours of incubation the NO formed in the cells diffused to the medium and was converted to 
nitrite in the presence of oxygen. Protein content of cell culture medium was precipitated with 200 mM ZnSO4. 
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One hundred microliters of each samples were applied to the reaction chamber, where nitrite was converted to 
NO by sodium iodide and was liberated by purging. The NO liberated was converted by ozone to NO2 and chemi-
luminescence of NO2 equivalent to NO formation was determined.
Nitric-oxide measurement with DAF-2 DA. The BPAE cells were seeded on 13 mm diameter coverslips 
which were placed in 24 well plates before seeding. The cells were then cultured until 60–80% of confluence. The 
culturing media was then replaced with the reaction buffer, which includes 1 μ M β -NADH, arginine substrate, 
25 μ M 4,5-diaminofluorescein diacetate (DAF-2 DA) provided by the manufacturer and the cells were incubated 
for 2 hours at 37 °C. Then PMA or EGCG was added to the corresponding wells for 1 hour. In parallel, non-treated 
coverslips (control) were also incubated with reaction buffer. Afterward the cells were washed with PBS and fixed 
in 4% (v/v) paraformaldehyde (PFA) solution for 10 minutes at room temperature. After washing three times 
with PBS the samples were mounted with 4.3 (m/v) Mowiol and prepared for confocal microscopy. The DAF-2 
was excited at 488 nm, and the detection range was 500–580 nm (Munhoz et al.)54. The intensity of single cell 









, which was based on the dye uptake equation described previously (Nagy et al.)55.
Pull-down assays. GST-MYPT1 pull-down experiments were carried out by coupling of GST (in control 
experiments) or GST-MYPT1 to glutathione-Sepharose beads (Lontay et al.)49, then the HUVEC lysate was 
applied to the resin and incubated for 3 hours at 4 °C. The resin was washed three times with washing buffer (1 M 
NaCl, 20 mM Tris-HCl, pH 7.4, 0.1% (v/v) Triton X-100), then boiled for 10 minutes with SDS sample buffer 
and subjected to immunoblot analysis with anti-eNOS antibody. Pull-down of overexpressed c-myc-eNOS or 
FLAG-MYPT1 from tsA201 cell lysate were carried out using anti-c-myc and anti-FLAG M2 antibody-coupled 
EZviewTM Red affinity gel and analyzed with anti-MYPT1 and anti-eNOS or with anti-c-myc and anti-FLAG 
antibodies.
In vitro phosphorylation/dephosphorylation assays. C-myc-eNOS was overexpressed in tsA201 cells 
and the cells were lysed in lysis buffer containing 1% (v/v) Triton X-100, 150 mM NaCl, 50 mM Tris–HCl (pH 
7.4), 0.1% (m/v) SDS, 1% (m/v) Na-deoxycholtate, 20 mM EDTA and 0.5% (v/v) protease inhibitor mix, centri-
fuged (10 000 g, 10 min) and the supernatant was bound to EZviewTM Red anti-c-Myc affinity gel. The gel was 
washed three times with a solution containing 1% (v/v) Triton X-100, 300 mM NaCl, 50 mM Tris–HCl (pH 7.4), 
0.1% (m/v) SDS, 1% (m/v) Na-deoxycholtate, 20 mM EDTA and 0.5% (v/v) protease inhibitor mix. Next, the 
affinity gel matrix was resuspended in ROCK assay buffer (30 mM Tris–HCl (pH 7.5), 85 mM KCl, 5 mM MgCl2, 
1 mM EGTA, 1 mM dithiothreitol (DTT) and 1 μ M microcystin-LR (MC-LR). Twenty percent of the gel was 
removed and boiled in hot SDS sample buffer (ROCK, 0 min). Phosphorylation of c-myc-eNOS was started by 
addition of 0.2 mM ATP in the presence of 5 mU/mL ROCK and the mixture was incubated for 60 min, followed 
by 6 washing steps with 20 mM Tris-HCl (pH 7.5) to remove MC-LR, ATP and Mg2+. The gel was resuspended 
again in 100 μ l 20 mM Tris-HCl (pH 7.5) buffer and another 20% of the initial gel amount was removed and boiled 
in SDS sample buffer (ROCK 60 min). The ROCK-phosphorylated sample was divided into three equal aliqouts 
and was incubated for 15 min with 15 nM purified FLAG-MYPT1, 5 nM purified native rabbit skeletal muscle 
PP1c52 or 5 nM PP1c plus 15 nM FLAG-MYPT1. The reactions were stopped by adding hot SDS sample buffer, 
then the samples were boiled for 5 minutes and subjected to Western blotting.
Assay of protein phosphatase activity. The assay of phosphatase activity of BPAECs was carried out 
as previously described for THP-1 cells31. Prior to treatments, BPAECs were incubated in serum-free medium 
for 16 h, then cells were untreated (control), or treated with 10 nM CLA for 30 min, or with 20 μ M EGCG for 
1 hour. Cells were collected by centrifugation (600 g, 5 min) and washed with phosphate buffered saline (PBS) fol-
lowed by washing with TBS containing 0.1 mM EDTA. Cells were resuspended in 100 μ l ice-cold TBS containing 
0.1 mM EDTA supplemented with 0.5% (v/v) protease inhibitor cocktail and 50 mM 2-mercaptoethanol. Cells 
were lysed by sonication on ice, then clarified by centrifugation (13 000 g, 10 min). The phosphatase activity of the 
supernatants was determined at 30 °C in 20 mM Tris–HCl (pH 7.4) and 0.1% (v/v) 2-mercaptoethanol with 1 μ 
M 32P-MLC20 in the absence or presence of 2 μ M His-inhibitor-2 (I2)31. The reaction was initiated by addition of 
the substrate. After 10-min incubation, the reaction was terminated by the addition of 200 μ l 10% TCA and 200 μ 
l 6 mg/ml BSA. The precipitated proteins were collected by centrifugation and the released 32Pi was determined 
from the supernatant (370 μ l) in a scintillation counter.
Immunofluorescence and confocal microscopy. BPAECs and HPAECs were plated on gelatin-coated 
glass coverslips and were grown for 24 hours. After fixation with 4% (v/v) PFA for 10 minutes, the cells were 
permeabilized with 0.1% (v/v) Triton X-100, 4% (m/v) BSA and 0.01% (m/v) NaN3 in PBS (pH 7.5) for 1 hour 
followed by three washing steps with 4% (m/v) BSA in PBS to block the nonspecific binding sites and once with 
antibody diluting solution (0.1% (v/v) Triton X-100, 0.1% (m/v) BSA and 0.01% (m/v) NaN3 in PBS (pH 7.5)). 
After blocking the cells were incubated overnight at 4 °C with mouse monoclonal anti-eNOS in 1:250, or with rab-
bit polyclonal anti-MYPT11–296 antibody in 1:100 dilution. Next, the cells were washed gently (three times) with 
PBS and incubated with goat polyclonal Alexa-488 (1:250) or goat polyclonal Alexa-546 (1:250) conjugated sec-
ondary antibodies for 1 hour at room temperature. Finally, the cells were washed three times with PBS and cov-
ered in Prolong Gold Antifade mounting medium. The localization of the specifically labelled eNOS and MYPT1 
was visualized using a confocal microscope (Olympus Fluoview 1000, Hamburg, Germany) equipped with 60X 
UPLSAPO (NA 1.35) oil immersion objective, or with Leica X8 confocal microscope (Leica Microsystems CMS 
GmbH, Mannheim, Germany). The optical thickness of the co-localization images was 1 μ m.
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Duolink poximity ligation assay. BPAECs cultured in 24 well plates on glass coverslips were fixed with 
4% PFA solution for 10 minutes, permeabilized with 0.1% (v/v) Triton X-100 for 10 minutes and blocked with 5% 
(m/v) BSA in PBS. The proximity ligation assay (PLA) was carried out according to the manufacturer’s instruc-
tions. Briefly, to visualize the interaction between eNOS and MYPT1 the samples were stained with mouse 
anti-eNOS (1:400) and rabbit anti-MYPT11–296 (1:500) antibodies overnight, at 4 °C prior to incubation with PLA 
probes for 1 hour at 37 °C. Then, ligase was added to hybridize the probes and after the rolling-circle amplification 
(RCA) the labelled probes were hybridized to the RCA product. After washing three times with PBS the samples 
were mounted with 4.3 (m/v) Mowiol and prepared for confocal microscopy.
Surface plasmon resonance measurement. Interaction of GST-MYPT1 with c-myc-eNOS was ana-
lyzed by surface plasmon resonance based binding experiments using a Biacore 3000 instrument (GE Healthcare, 
Uppsala, Sweden) as described previously (Kolozsvári et al.)25. Anti-GST was immobilized on CM5 sensor chip 
by amine-coupling according to the instructions of the manufacturers. On one surface recombinant GST while 
on the two other surfaces full-length GST-MYPT1 were immobilized in running buffer containing 10 mM Hepes 
(pH 7.4), 0.15 M NaCl, 3 mM EDTA, and 0.005% (v/v) Surfactant P20. C-myc-eNOS at 0.5 μ M or 1 μ M in running 
buffer was injected over the surfaces and the amount of the captured analyte was determined from the changes 
of the resonance signal expressed as response units (RU). The surface (with immobilized recombinant GST) was 
treated identically to the GST-MYPT1 surfaces to determine unspecific binding which was subtracted from the 
data obtained with the GST-MYPT1 surfaces.
Transendothelial permeability measurement. Transendothelial electrical resistance (TER) of BPAECs 
was measured using electric cell-substrate impedance sensing (ECIS) instrument, Model 1600 R (Applied 
BioPhysics, Troy, NY, USA) as described (Bogatcheva et al.)56. Approximately equal numbers (3.5 × 104/well) 
of BPAE cells were seeded on electrode arrays (8W10E) and the experiments were performed on wells that 
achieved > 1000 Ω of baseline steady-state resistance. One hour before treating the cells the media was changed 
to serum-free MEM and the changes in the initial resistance were measured, then after the different treatments 
with PMA, CLA TM or EGCG the data were normalized to the initial resistance values and plotted as normalized 
resistance.
Statistical analysis. Statistical significance of differences measured between control and treated sam-
ples were determined by Student’s t-test for two groups or by analysis of variance (ANOVA) followed by 
Newman-Keuls post hoc testing. Results with P < 0.05 were considered statistically significant.
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